Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Cancer Discov. 2016 Feb 19;6(4):400–413. doi: 10.1158/2159-8290.CD-15-1032

Figure 4. CD40 agonist induces a shifts in the MMP gene expression profile in tumors that is dependent on inflammatory monocytes and IFN-γ.

Figure 4

(A) Heat map showing global gene expression in tumor homogenates from mice with implanted PDAC tumors one day after treatment with control (n = 9) or anti-CD40 (n = 10). Statistical significance was determined using one-way Anova with Bonferroni correction for multiple comparisons testing. P values are shown to right of heat map. (B) Tumor-bearing mice were treated with control or anti-CD40 with or without depletion of Ly6C+ inflammatory monocytes or Ly6G+ granulocytes. Shown is relative transcript expression for Mmp3, Mmp9, Mmp10, Mmp12, and Mmp13. n=5-10 mice per group. (C) qRT-pCR analysis from tumor homogenate cDNA isolated one day after treatment. Displayed are fold changes in Mmp genes relative to control treatment. For panels B-C, significance testing was performed using unpaired 2-tailed Student's t test. *, P < 0.05; **, P<0.01; ****, P<0.0001.